GlassScriptPhysician profile
Julie Therese Abraham
NPI 1831486182
$11,418.86
in general payments reported to CMS, 2019-2025
35 companies · $2,319 in 2025
The $2,319 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $954 · 2021: $1,608 · 2022: $1,448 · 2023: $2,397 · 2024: $2,017 · 2025: $2,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,685 · Education: $48.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,685.13 |
| Education | $48.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,898.49 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $1,820.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,661.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,227.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,004.64 | 2019-2025 | Dupixent |
| Amgen INC. | $539.75 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $521.88 | 2021-2025 | |
| Optinose US, INC. | $438.03 | 2020-2025 | |
| Kaleo, INC. | $327.53 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $309.18 | 2019-2024 | Xolair |
| Abbvie INC. | $249.89 | 2022-2023 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $188.25 | 2021-2025 | Takhzyro, Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $146.01 | 2025 | Neffy |
| Leo Pharma INC. | $118.78 | 2023 | Adbry |
| Csl Behring | $110.07 | 2020-2025 | Haegarda, Andembry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $94.77 | 2025 | Dawnzera |
| Lilly USA, LLC | $76.63 | 2024-2025 | Ebglyss |
| Galderma Laboratories, L.P. | $74.66 | 2025 | Nemluvio |
| Incyte Corporation | $71.18 | 2022-2024 | Opzelura |
| Biocryst US Sales Co., LLC | $69.51 | 2022-2024 | Orladeyo |
| Regeneron Pharmaceuticals, INC. | $58.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.25 | 2019-2022 | |
| Grifols USA, LLC | $48.24 | 2022-2023 | Prolastin-C Liquid |
| Azurity Pharmaceuticals, INC. | $42.88 | 2025 | Alvesco |
| Aimmune Therapeutics, INC. | $36.50 | 2021-2022 | |
| Monaghan Medical Corporation | $34.08 | 2024 | Aerobika |
| Greer Laboratories, INC. | $27.42 | 2021-2025 | Oralair |
| Teva Pharmaceuticals USA, INC. | $27.07 | 2021 | |
| Covis Pharma Gmbh | $26.09 | 2019 | |
| Pharming Healthcare, INC. | $25.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $22.50 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Alk-Abello, INC | $16.48 | 2019 | |
| Hikma Pharmaceuticals USA | $16.21 | 2023 | Ryaltris |
| Blueprint Medicines Corporation | $15.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.